SOLARA — Solara Active Pharma Sciences Balance Sheet
0.000.00%
- IN₹26.40bn
- IN₹32.73bn
- IN₹13.69bn
Annual balance sheet for Solara Active Pharma Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 464 | 87.3 | 84.4 | 39.5 | 599 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6,037 | 6,074 | 3,970 | 3,810 | 4,388 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 12,393 | 11,875 | 8,008 | 7,287 | 8,581 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 11,374 | 11,591 | 11,142 | 10,765 | 10,552 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 29,450 | 28,993 | 23,510 | 22,318 | 23,326 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10,634 | 11,011 | 12,429 | 9,441 | 8,939 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 14,201 | 13,991 | 14,171 | 11,376 | 10,797 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 15,249 | 15,002 | 9,339 | 10,942 | 12,529 |
| Total Liabilities & Shareholders' Equity | 29,450 | 28,993 | 23,510 | 22,318 | 23,326 |
| Total Common Shares Outstanding |